AbbVie's Q3 2026 earnings release, delivered before the open on October 30, featured global Skyrizi net revenues of $5.776 billion, reflecting 22.7% reported growth and beating consensus estimates near $5.71–5.72 billion. Strong volume uptake across psoriasis, psoriatic arthritis, and Crohn’s indications, alongside recent FDA approval of subcutaneous induction for Crohn’s, drove the immunology portfolio to $9.165 billion. Traders focus on Skyrizi’s contribution to the full-year $67.6 billion revenue guide and 2027 outlook, with label expansions and market-share gains offsetting biosimilar pressure on Humira. Upcoming catalysts include further indication reviews and Q4 formulary access updates for the new Crohn’s regimen. Market-implied odds reflect this sustained double-digit trajectory amid competitive IL-23 dynamics.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено1H6H1D7D30DALL
View resolved

Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання